

**E-Filed**

**Date of Deposit: November 8, 2010**

Attorney Docket No. 27331-501CIP2A

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S):	Francisco Sanchez-Madrid	Confirmation No.:	1583
SERIAL NUMBER:	10/770,639	EXAMINER :	SKELDING, ZACHARY S
FILING DATE:	February 2, 2004	ART UNIT :	1644
FOR:	IMMUNE REGULATION BASED ON THE DEPLETION OF CD69+ CELLS		

**VIA EFS-WEB**

Commissioner for Patents  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith.

This Information Disclosure Statement is being filed after the mailing date of a Notice of Allowance in the above-identified case, but before payment of the issue fee and is accompanied by the statement under § 1.97 (e) and fee set forth in § 1.17(p).

Pursuant to 37 C.F.R. §1.97(e), each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in counterpart European Application 04707410.9 not more than three months prior to the filing of the information disclosure statement.

Pursuant to 37 C.F.R. § 1.704(d), each item of information in this Information Disclosure Statement was first cited in a communication from a foreign patent office for counterpart European Application 04707410.9, which was communicated to Applicants' U.S. Attorneys on October 13, 2010. As such this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

It is respectfully requested that the Examiner consider completely the cited information,

**APPLICANT: Francisco Sanchez-Madrid**  
**U.S.S.N.: 10/770,639**

along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed PTO Form SB/08(a) with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **27331-501CIP2A**.

Respectfully submitted,

/ Sheridan Snedden/  
Cynthia A. Kozakiewicz, Reg. No. 42,764  
Sheridan K. Snedden, Reg. No. 55,998  
Attorneys for Applicants  
MINTZ, LEVIN  
Tel: (202) 434-7327  
Fax: (617) 542-2241  
**Customer no.: 30623**

Dated: November 8, 2010

5067828v.1